TY - JOUR
T1 - The effects of the aromatase inhibitor Δ1-testolactone on gonadotropin release and steroid metabolism in polycystic ovarian disease
AU - Dunaif, Andrea
AU - Longcope, Christopher
AU - Canick, Jacob
AU - Badger, Thomas
AU - Crowley, William F.
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1985/4
Y1 - 1985/4
N2 - This study was designed to examine the importance of aromatization in the gonadotropin secretory dynamics of polycystic ovarian disease (PCOt)) by using the aromatase inhibitor Δ1 testolactone (TL) as a probe and to determine the effects of TL on steroid metabolism in vivo and in vitro. The pulsatile patterns of gonadotropin secretion and peripheral steroid levels were studied in eight women with PCOD before and during TL administration. There was a significant fall in peripheral estrone (E1) levels, a rise in peripheral androstenedione levels, and an increase in the androstenedione/E1 ratio during TL administration in these women. Isotopic determinations of androgen and estrogen production and metabolism before and during TL administration in two women confirmed a 90-95% decrease in the overall rate of aromatization. One patient also had an increase in the production and clearance rates of estradiol and Ei during TL administration, suggesting resistance to TL of the ovarian aromatase enzyme system. There were significant increases in both mean LH pulse amplitude [1.2 ± 0.3 (SE) mlU/ ml LER-907 before vs. 1.7 ± 0.3 mlU/ml LER-907 during TL, P < 0.05, paired t test] and frequency per 6 h (median: 3 before vs. 4 during TL, P < 0.05, Wilcoxon signed rank test). Mean levels of LH and FSH did not, however, change significantly during TL administration. TL maximally inhibited neonatal rat hypothalamic aromatase in vitro at concentrations of 200 μM, a level theoretically obtainable during pharmacological therapy. These data suggest that: 1) in humans TL is a potent inhibitor of peripheral but not ovarian aromatase, and of hypothalamic aromatase in rats; 2) TL administration increases LH pulse amplitude and frequency in PCOD,. either directly via hypothalamic aromatase inhibition, or indirectly by alterations in gonadal steroid metabolism; and 3) because of the multiple potential actions of TL, its usefulness as a probe in studies of gonadotropin secretion in PCOD is limited.
AB - This study was designed to examine the importance of aromatization in the gonadotropin secretory dynamics of polycystic ovarian disease (PCOt)) by using the aromatase inhibitor Δ1 testolactone (TL) as a probe and to determine the effects of TL on steroid metabolism in vivo and in vitro. The pulsatile patterns of gonadotropin secretion and peripheral steroid levels were studied in eight women with PCOD before and during TL administration. There was a significant fall in peripheral estrone (E1) levels, a rise in peripheral androstenedione levels, and an increase in the androstenedione/E1 ratio during TL administration in these women. Isotopic determinations of androgen and estrogen production and metabolism before and during TL administration in two women confirmed a 90-95% decrease in the overall rate of aromatization. One patient also had an increase in the production and clearance rates of estradiol and Ei during TL administration, suggesting resistance to TL of the ovarian aromatase enzyme system. There were significant increases in both mean LH pulse amplitude [1.2 ± 0.3 (SE) mlU/ ml LER-907 before vs. 1.7 ± 0.3 mlU/ml LER-907 during TL, P < 0.05, paired t test] and frequency per 6 h (median: 3 before vs. 4 during TL, P < 0.05, Wilcoxon signed rank test). Mean levels of LH and FSH did not, however, change significantly during TL administration. TL maximally inhibited neonatal rat hypothalamic aromatase in vitro at concentrations of 200 μM, a level theoretically obtainable during pharmacological therapy. These data suggest that: 1) in humans TL is a potent inhibitor of peripheral but not ovarian aromatase, and of hypothalamic aromatase in rats; 2) TL administration increases LH pulse amplitude and frequency in PCOD,. either directly via hypothalamic aromatase inhibition, or indirectly by alterations in gonadal steroid metabolism; and 3) because of the multiple potential actions of TL, its usefulness as a probe in studies of gonadotropin secretion in PCOD is limited.
UR - http://www.scopus.com/inward/record.url?scp=0021951006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021951006&partnerID=8YFLogxK
U2 - 10.1210/jcem-60-4-773
DO - 10.1210/jcem-60-4-773
M3 - Article
C2 - 3919053
AN - SCOPUS:0021951006
SN - 0021-972X
VL - 60
SP - 773
EP - 780
JO - Journal of clinical endocrinology and metabolism
JF - Journal of clinical endocrinology and metabolism
IS - 4
ER -